Feb 20, 2015:

MAKE THE LARGEST HUMAN IMAGE OF A HEART

Doctors and Ranbaxy employees participated in the event to break the existing Guinness World Records™

Gurgaon, India: Ranbaxy Laboratories Limited (Ranbaxy) and APICON 2015 (70th Annual Conference of Association of Physicians of India) today broke the Guinness World Record™ for making the largest human image of a heart in Gurgaon, Haryana, India.

Realising the need for a proactive emphasis on preventive healthcare and raising awareness about heart disease in India, Ranbaxy & APICON assembled 982 people (consisting of doctors and Ranbaxy employees) to form a human heart. The formation of the human heart was achieved in 1 hour 15 minutes. The participants wore T-shirts and caps of distinct colors to bring out the correct anatomical representation of this central body organ. The creation beat the world record for the largest image of a human organ ever formed by a group of humans assembled together. The earlier record was set on February 20, 2014, in Liverpool, UK, when 687 people came together to form the image of the largest human brain on World Encephalitis Day.

On the milestone achievement, Ms. Lucia Sinigagliesi, Guinness World Records™ Adjudicator said, "Today's record attempt was very well organised and it was great to see the enthusiasm of the crowd. The participants, all wearing colour clothing corresponding with their part of the image of the organ, were perfectly arranged in formation of a human heart. I congratulate Ranbaxy and APICON for their record achievement. Initiatives taken to spread awareness about the importance of fitness are a good message for the public. I appreciate team Ranbaxy's efforts in this endeavour."

On this occasion, Mr. Rajeev Sibal, Vice President & Head-India Region, Ranbaxy said, "It gives me immense pleasure to witness the successful conclusion of the Guinness World Record™ attempt by Ranbaxy and APICON. The event would be truly successful when each one of us takes the challenge of doing exercise for at least 30 minutes daily and spread the message to more and more number of people. Ranbaxy will always continue its endeavour to spread the importance of exercise and fitness to larger masses and motivate people to lead a healthier life."

Dr Ashok. K Taneja, Organising Secretary, APICON 2015 said, "When the entire disease management is shifting towards prevention, mass initiatives like this would help to create more and more awareness on importance of exercise and fitness which can avoid many diseases. I congratulate both the teams for the successful completion of the record."

Indians have genetic predisposition to the Coronary Artery Disease (CAD). Changing lifestyle, urbanisation, unhealthy food habits, decreasing physical activity, rising stress levels and rampant obesity have made the problem more severe. As a result, the country has seen a significant increase in the number of heart disease patients over the past 20 years. Worse, the average age of a heart patient in India is in the early fifties, compared to seventies in developed nations like the US.

The 70th Annual Conference of the Association of Physicians of India (APICON) is being organised at Gurgaon in the Delhi-NCR region from 19th - 22nd February, 2015. The theme this year focuses on "Optimizing Patient Care." The event is especially significant as it marks the Platinum Jubilee of the long-standing Conference.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.


distributed by